A biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases
psithera.comWatertown, MassachusettsBiotech
1 source · checked 1 time, last 2h ago
The release describes Samsara BioCapital and Lightstone Ventures as “existing lead investors,” not as leads of this financing; “other existing investors” are unspecified.
3 sources
FinSMEs is dated December 16, 2025; the company’s December 10, 2025 dateline fixes the announcement day.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round | $25M | 2026-11-10 | not stated | 1 outlet. #69 in Trending |
1 source · checked 1 time, last 2h ago [ VERIFIED · CORRECTED ] read against 1 source
The release describes Samsara BioCapital and Lightstone Ventures as “existing lead investors,” not as leads of this financing; “other existing investors” are unspecified. | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $47.5M | 2025-12-10 | Lightstone Ventures, Samsara BioCapital | No recent discussion |
3 sources [ VERIFIED · CORRECTED ] read against 2 of 3 sources
FinSMEs is dated December 16, 2025; the company’s December 10, 2025 dateline fixes the announcement day. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]3 pages read: psithera.com, globenewswire.com, finsmes.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 of 3 sources·[ BRANDING ]logo and colour from the homepage | ||||